Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Chief Financial Officer | May 11, 2026 | May 12, 2026 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Chief Financial Officer | June 22, 2020 | June 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,161 |
Reported balance
After 2026-05-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-11 · Sale · Disposed 7,763 · Balance 84,161 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Includes the unvested portion of the reporting person's RSU grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Includes the unvested portion of the reporting person's RSU grants.
Unity Biotechnology, Inc.
Report date June 22, 2020 · Filed June 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 161,027 |
Reported balance
After 2020-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-22 · Tax withholding · Disposed 2,483 · Balance 161,027 F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting. F2: Includes Restricted Stock Units which vest over time measured from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the release of shares subject to vesting.
F2: Includes Restricted Stock Units which vest over time measured from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytomX Therapeutics, Inc.
Report date May 12, 2017 · Filed May 16, 2017
Section 16 reporting ended · disclosed 2017-05-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,756 |
Ending reported balance
After 2017-05-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-05-12 · Exercise / conversion · Acquired 9,980 · Balance 22,769 Row 2 · 2017-05-12 · Exercise / conversion · Acquired 9,987 · Balance 32,756 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 · Expires 2025-05-06 | Direct | 204,678 |
Reported balance
After 2017-05-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-05-12 · Exercise / conversion · Disposed 9,980 · Balance 204,678 F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61 · Expires 2025-08-25 | Direct | 85,891 |
Reported balance
After 2017-05-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-12 · Exercise / conversion · Disposed 9,987 · Balance 85,891 F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019.
F2: This option vests in 48 substantially equal monthly installments starting on August 28, 2015, with each additional installment vesting on the last day of the month starting in September 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2017 Filed May 16, 2017 20:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,987 | $6.61 | $66,061.01 |
DisclosureSEC source: 0001140361-17-021016 · doc1.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 9,980 | $4.47 | $44,638.54 |
DisclosureSEC source: 0001140361-17-021016 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-015543 · doc1.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,658 Underlying: Common Stock · 3,000 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 16:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 3,000 | $4.47 | $13,418.40 |
DisclosureSEC source: 0001140361-17-015543 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,517 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-012870 · doc1.xml · derivative · entry 4 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,658 Underlying: Common Stock · 21,517 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 11,517 | $20.00 | $230,340.00 |
DisclosureSEC source: 0001140361-17-012870 · doc1.xml · nonDerivative · entry 3 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,789 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 10,000 | $19.60 | $196,000.00 |
DisclosureSEC source: 0001140361-17-012870 · doc1.xml · nonDerivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,306 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 22:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 21,517 | $4.47 | $96,241.24 |
DisclosureSEC source: 0001140361-17-012870 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 00:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-17-011297 · doc1.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,175 Underlying: Common Stock · 2,500 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 00:22 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 2,500 | $4.47 | $11,182.00 |
DisclosureSEC source: 0001140361-17-011297 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:51 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 84,000 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001140361-17-003155 · doc1.xml · derivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 00:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 1,289 | $9.10 | $11,723.46 |
DisclosureSEC source: 0001140361-16-088447 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,289 F1 · kind: 1,289 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 18:32 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001140361-16-081383 · doc1.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,675 Underlying: Common Stock · 4,000 shares Expires 2025-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests 25% on May 4, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month, except the final installment, which shall vest on May 4, 2019. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 18:32 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | Exercise / conversionCommon Stock | 4,000 | $4.47 | $17,891.20 |
DisclosureSEC source: 0001140361-16-081383 · doc1.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.